Clinical Trial: Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction: Mechanisms of Multi-target Anti-inflammatory Action

Brief Summary: The present study is designed to confirm the therapeutic effects of heat-clearing and blood-activating Chinese medicinal components in treatment of Acute Cerebral Infarction (ACI) and to investigate the therapeutic mechanisms of multi-target anti-inflammatory action involved from the standpoint of pathology, cell and molecular biology, as well as immunology.

Detailed Summary:

The present study is designed to confirm the therapeutic effects of heat-clearing and blood-activating Chinese medicinal components in treatment of Acute Cerebral Infarction (ACI) and to investigate the therapeutic mechanisms of multi-target anti-inflammatory action involved from the standpoint of pathology, cell and molecular biology, as well as immunology. In particular, investigators choose heat-clearing Ixeris of sonchifolia Hance(Kudiezi Injection) and blood-activating Panax notoginseng saponins(Xueshuantong Injection)as the therapeutic interventions to carry out the investigation, applying the key techniques such as Lentivirus-mediated RNA interference, co-immunoprecipitation and immunomagnetic beads.

With the joint efforts, investigators hope to find out the combined therapeutic targets based on better understanding of the inflammatory pathology in ACI and illuminate the synergistic mechanisms involved, which may validate the Chinese medicine theory of"cerebral vascular damage due to heat toxicity" in the pathogenesis of ACI and yield new therapeutic strategies for ACI. As an international science and technology cooperation project, the study is of great significance in establishing an international technology platform of intervention target system for the treatment of ACI; moreover, it marks a key step forward for China to enhance China's international brands through exploring a successful mode of foreign cooperation in Chinese medicine.


Sponsor: Yunling Zhang

Current Primary Outcome: modified Rankin scale [ Time Frame: 180 days ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Barthel index [ Time Frame: 180 days ]
  • national institute of health stroke scale [ Time Frame: 180 days ]
  • Glasgow coma scale [ Time Frame: 180 days ]
  • scores of Chinese medicine symptoms [ Time Frame: 180 days ]
  • mortality rate [ Time Frame: 180 days ]
  • disability rate [ Time Frame: 180 days ]


Original Secondary Outcome:

  • Barthel index [ Time Frame: 180 days ]
  • national institute of health stroke scale [ Time Frame: 180 days ]
  • Glasgow coma scale [ Time Frame: 180 days ]
  • Chinese medicine syndrome [ Time Frame: 180 days ]
  • mortality rate [ Time Frame: 180 days ]
  • disability rate [ Time Frame: 180 days ]


Information By: Dongfang Hospital Affiliated to Beijing University of Chinese Medicine

Dates:
Date Received: September 5, 2015
Date Started: April 2015
Date Completion: April 2018
Last Updated: August 4, 2016
Last Verified: August 2016